Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Comprehensive assessment of PINK1 variants in Parkinson’s disease

View ORCID ProfileLynne Krohn, Francis P. Grenn, Mary B. Makarious, Jonggeol Jeffrey Kim, View ORCID ProfileSara Bandres-Ciga, View ORCID ProfileDorien A. Roosen, View ORCID ProfileZiv Gan-Or, Mike A. Nalls, Andrew B. Singleton, View ORCID ProfileCornelis Blauwendraat on behalf of the International Parkinson’s Disease Genomics Consortium (IPDGC)
doi: https://doi.org/10.1101/2020.01.21.20018101
Lynne Krohn
1Department of Human Genetics, McGill University, Montreal, Quebec, Canada
2Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Lynne Krohn
Francis P. Grenn
3Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mary B. Makarious
3Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jonggeol Jeffrey Kim
3Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sara Bandres-Ciga
3Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Sara Bandres-Ciga
Dorien A. Roosen
3Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Dorien A. Roosen
Ziv Gan-Or
1Department of Human Genetics, McGill University, Montreal, Quebec, Canada
2Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada
4Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ziv Gan-Or
Mike A. Nalls
3Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA
5Data Tecnica International, Glen Echo, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew B. Singleton
3Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cornelis Blauwendraat
3Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Cornelis Blauwendraat
  • For correspondence: cornelis.blauwendraat@nih.gov
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Multiple genes have been associated with monogenic Parkinson’s disease and Parkinsonism syndromes. Mutations in PINK1 (PARK6) have been shown to result in autosomal recessive early onset Parkinson’s disease. In the past decade, several studies have suggested that carrying a single heterozygous PINK1 mutation is associated with increased risk for Parkinson’s disease. Here we comprehensively assess the role of PINK1 variants in Parkinson’s disease susceptibility using several large datasets totalling 376,558 individuals including: 13,708 Parkinson’s disease cases and 362,850 controls. After combining these data, we did not find evidence to support a role for heterozygous PINK1 mutations as a risk factor for Parkinson’s disease.

Competing Interest Statement

Dr Nalls reported receiving support from a consulting contract between Data Tecnica International and the National Institute on Aging (NIA), National Institutes of Health (NIH), and consulting for the Michael J. Fox Foundation, Illumina Inc., Vivid Genomics, Lysosomal Therapeutics Inc., and Neuron23, Inc, among others. No other disclosures were reported. Dr. Gan-Or has received consultancy fees from Lysosomal Therapeutics Inc., Idorsia, Denali, Prevail Therapeutics, Deerfield, Ono Therapeutics, Deerfield and Inception Sciences.

Funding Statement

This work was supported in part by the Intramural Research Programs of the National Institute of Neurological Disorders and Stroke (NINDS), the National Institute on Aging (NIA), and the National Institute of Environmental Health Sciences both part of the National Institutes of Health, Department of Health and Human Services; project numbers 1ZIA-NS003154, Z01- AG000949-02 and Z01-ES101986. This research has been conducted using the UK Biobank Resource under Application Number 33601. Data used in the preparation of this article were obtained from the Parkinson's Progression Markers Initiative (PPMI) database (www.ppmiinfo.org/data). For up-to-date information on the study, visit www.ppmi-info.org. PPMI, a public-private partnership, is funded by the Michael J. Fox Foundation for Parkinson’s Research and funding partners, including AbbVie, Avid, Biogen, Bristol-Myers Squibb, Covance, GE Healthcare, Genentech, GlaxoSmithKline, Lilly, Lundbeck, Merck, Meso Scale Discovery, Pfizer, Piramal, Roche, Servier, Teva, UCB, and Golub Capital. Data and biospecimens used in preparation of this manuscript were obtained from the Parkinson’s Disease Biomarkers Program (PDBP) Consortium, part of the National Institute of Neurological Disorders and Stroke at the National Institutes of Health. Investigators include: Roger Albin, Roy Alcalay, Alberto Ascherio, DuBois Bowman, Alice Chen-Plotkin, Ted Dawson, Richard Dewey, Dwight German, Xuemei Huang, Rachel Saunders-Pullman, Liana Rosenthal, Clemens Scherzer, David Vaillancourt, Vladislav Petyuk, Andy West and Jing Zhang. The PDBP Investigators have not participated in reviewing the data analysis or content of the manuscript. DNA panels from the NINDS Human Genetics Resource Center DNA and Cell Line Repository (http://ccr.coriell.org/ninds) were used in this study, as well as clinical data. The McGill cohort was financially supported by the Michael J. Fox Foundation, the Canadian Consortium on Neurodegeneration in Aging (CCNA), Parkinson Canada, and the Canada First Research Excellence Fund (CFREF), awarded to McGill University for the Healthy Brains for Healthy Lives (HBHL) program. The access to part of the participants for this research has been made possible thanks to the Quebec Parkinson’s Network (http://rpqqpn.ca/en/). ZGO is supported by the Fonds de recherche du Québec - Santé (FRQS) Chercheurs-boursiers award, and is a Parkinson Canada New Investigator awardee. The access to part of the participants for this research has been made possible thanks to the Quebec Parkinson’s Network (http://rpq-qpn.ca/en/).

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

NA

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.
Back to top
PreviousNext
Posted January 27, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Comprehensive assessment of PINK1 variants in Parkinson’s disease
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Comprehensive assessment of PINK1 variants in Parkinson’s disease
Lynne Krohn, Francis P. Grenn, Mary B. Makarious, Jonggeol Jeffrey Kim, Sara Bandres-Ciga, Dorien A. Roosen, Ziv Gan-Or, Mike A. Nalls, Andrew B. Singleton, Cornelis Blauwendraat
medRxiv 2020.01.21.20018101; doi: https://doi.org/10.1101/2020.01.21.20018101
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Comprehensive assessment of PINK1 variants in Parkinson’s disease
Lynne Krohn, Francis P. Grenn, Mary B. Makarious, Jonggeol Jeffrey Kim, Sara Bandres-Ciga, Dorien A. Roosen, Ziv Gan-Or, Mike A. Nalls, Andrew B. Singleton, Cornelis Blauwendraat
medRxiv 2020.01.21.20018101; doi: https://doi.org/10.1101/2020.01.21.20018101

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Genetic and Genomic Medicine
Subject Areas
All Articles
  • Addiction Medicine (179)
  • Allergy and Immunology (431)
  • Anesthesia (99)
  • Cardiovascular Medicine (943)
  • Dentistry and Oral Medicine (178)
  • Dermatology (109)
  • Emergency Medicine (260)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (419)
  • Epidemiology (8971)
  • Forensic Medicine (4)
  • Gastroenterology (418)
  • Genetic and Genomic Medicine (1938)
  • Geriatric Medicine (190)
  • Health Economics (400)
  • Health Informatics (1323)
  • Health Policy (657)
  • Health Systems and Quality Improvement (517)
  • Hematology (212)
  • HIV/AIDS (416)
  • Infectious Diseases (except HIV/AIDS) (10772)
  • Intensive Care and Critical Care Medicine (571)
  • Medical Education (200)
  • Medical Ethics (54)
  • Nephrology (221)
  • Neurology (1819)
  • Nursing (108)
  • Nutrition (271)
  • Obstetrics and Gynecology (351)
  • Occupational and Environmental Health (469)
  • Oncology (992)
  • Ophthalmology (296)
  • Orthopedics (111)
  • Otolaryngology (182)
  • Pain Medicine (126)
  • Palliative Medicine (44)
  • Pathology (265)
  • Pediatrics (576)
  • Pharmacology and Therapeutics (275)
  • Primary Care Research (234)
  • Psychiatry and Clinical Psychology (1892)
  • Public and Global Health (4111)
  • Radiology and Imaging (674)
  • Rehabilitation Medicine and Physical Therapy (364)
  • Respiratory Medicine (548)
  • Rheumatology (224)
  • Sexual and Reproductive Health (190)
  • Sports Medicine (177)
  • Surgery (207)
  • Toxicology (38)
  • Transplantation (109)
  • Urology (80)